API 99% Sunifiram White Raw Power CAS 314728-85-3

Sunifiram More Info

Sunifiram is a synthetic compound belonging to a novel class of nootropic agents known as the racetam analogs, with the CAS Registry Number 314728-85-3. Its molecular structure is a low molecular weight derivative of piracetam, simplified to  core connected to a carbonyl-containing side chain. This structural simplification was designed to enhance potency and cognitive-enhancing effects compared to its predecessor while maintaining a favorable safety profile. It is typically encountered as a white or off-white crystalline powder in research settings.

The precise pharmacological mechanism of action for sunifiram is not fully elucidated but is believed to differ from classical racetams. Research suggests its potent cognitive effects are primarily mediated through the modulation of glutamatergic neurotransmission, specifically as a positive allosteric modulator of the AMPA subtype of glutamate receptors. This action enhances fast excitatory synaptic transmission, which is critical for learning and memory processes. Additionally, it may influence cholinergic and monoaminergic systems, and has been shown to increase the expression of neurotrophic factors in animal models.

The primary interest and application for sunifiram lie within the domain of nootropic research. It is studied for its potential to enhance cognitive functions such as memory formation, learning capacity, and attention. Preclinical studies in rodents have demonstrated significant improvements in memory retention and cognitive performance in various behavioral models at very low doses. Due to these findings, it has been marketed as a "smart drug" or dietary supplement for cognitive enhancement, although such use is based on limited human data and occurs outside of formal medical regulation.

From a biochemical perspective, sunifiram exhibits very high potency, with active doses in the microgram to low milligram range in animal studies, which is significantly lower than traditional racetams. Its pharmacokinetic properties in humans are not well-characterized, but its low molecular weight suggests potential for good absorption. In research contexts, it is typically administered orally or via intraperitoneal injection to assess its effects on cognitive and behavioral endpoints.